DPYD DPYD*13 HOMOZYGOSITY

CI-VAR-00000620Explore in graph →NP_000101.2:p.Ile560SerNM_000110.3:c.1679T>GClinVar 88975 CIViC 738 rs55886062

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
DPYD DPYD*13 HOMOZYGOSITY	Capecitabine + Fluorouracil + TegafurSubstitutes	Predictive	A	Supports Adverse Response	5	accepted	EID1801 The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD2A, 13 or rs67… (full text at CIViC) PMID 23988873 · Caudle et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.